QNCX · As filed with the SEC
Quince Therapeutics balance sheet, by fiscal year
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD thousands
| USD thousands | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | — | 6,212 | 20,752 | 44,579 |
| Short-term investments | — | 34,572 | 54,307 | 45,602 |
| Cash and cash equivalents | 5,809,000 | — | — | — |
| Short-term investments | 11,943,000 | — | — | — |
| Prepaid expenses and other current assets | 5,144,000 | 3,252,000 | 2,381,000 | 3,567,000 |
| Total current assets | 22,896,000 | 44,036,000 | 77,440,000 | 93,748,000 |
| Assets held for sale | — | — | 10,000 | — |
| Property and equipment, net | 595,000 | 315,000 | 234,000 | 393,000 |
| Operating lease right-of-use assets | 453,000 | 498,000 | 385,000 | 291,000 |
| Long term investments | — | — | 0 | 3,578,000 |
| Goodwill | — | 0 | 17,625 | — |
| Intangible assets | 67,819,000 | 60,045,000 | 63,672,000 | 5,900,000 |
| Other assets | 1,760,000 | 9,584,000 | 8,456,000 | 0 |
| Equity investments in Lighthouse Pharmaceuticals, Inc. | — | — | 78,000 | — |
| Total assets | 93,523,000 | 114,478,000 | 167,900,000 | 103,910,000 |
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | 2,223,000 | 2,903,000 | 2,033,000 | 570,000 |
| Accrued expenses and other current liabilities | 10,608,000 | 4,375,000 | 3,436,000 | 2,499,000 |
| Current portion of debt | 18,026,000 | — | — | — |
| Short-term contingent consideration | 12,369,000 | 0 | 4,103,000 | — |
| Total current liabilities | 43,226,000 | 7,278,000 | 9,572,000 | 3,069,000 |
| Long-term debt | 0 | 14,321,000 | 13,429,000 | — |
| Long-term operating lease liabilities | 330,000 | 394,000 | 321,000 | 0 |
| Long-term contingent consideration | 51,961,000 | 56,691,000 | 53,603,000 | — |
| Deferred tax liabilities | 0 | 4,963,000 | 5,304,000 | 248,000 |
| Warrant liabilities | 32,150,000 | — | — | — |
| Other long-term liabilities | 1,570,000 | 685,000 | 587,000 | — |
| Total liabilities | 129,237,000 | 84,332,000 | 82,816,000 | 3,317,000 |
| Stockholders' (deficit) equity: | ||||
| Preferred stock, $0.001 par value, 10,000,000 authorized, no shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value, 250,000,000 shares authorized, 55,725,291 and 44,001,643 issued and outstanding as of December 31, 2025 and 2024, respectively. | 55,000 | 44,000 | 43,000 | 36,000 |
| Additional paid in capital | — | 406,609 | 401,638 | 389,105 |
| Additional paid in capital | 418,932,000 | — | — | — |
| Accumulated other comprehensive income (loss) | 5,750,000 | (35,000) | 3,047,000 | (289,000) |
| Accumulated deficit | (460,451,000) | (376,472,000) | (319,644,000) | (288,259,000) |
| Total stockholders' (deficit) equity | (35,714,000) | 30,146,000 | 85,084,000 | 100,593,000 |
| Total liabilities and stockholders' equity (deficit) | 93,523,000 | 114,478,000 | 167,900,000 | 103,910,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.